ATLASInvesco S&P MidCap 400 GARP ETF (GRPM): outlook, holdings and fees
Invesco S&P MidCap 400 GARP ETF (GRPM) is an exchange-traded fund and is managed by Invesco. The expense ratio is 0.36% and the yield is 0.56%. The ten largest holdings are 27% of the fund.
Fund data as of Oct 14, 2026 · Price Nov 2, 2026
ATLAS view on GRPM
| Last price | $147.59 (+2.0%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 55% |
| Likely 1-month range (50%) | $144.44 – $152.27 |
| Normal 1-day range (±1σ) | ±0.9% |
| Distribution yield | 0.56% |
ATLAS probabilities use the same calibrated model as every stock page. A fair value is shown for companies, not funds; the holdings below link to the fair value of each company.
GRPM fund facts
| Issuer | Invesco |
|---|---|
| Theme | Other strategies |
| Assets under management | $506M |
| Expense ratio | 0.36% |
| Number of holdings | 50 |
| Portfolio turnover | 33% |
| Inception | Dec 3, 2010 |
| Exchange | NYSE |
The underlying index is designed to track the performance of the top 60 growth stocks in the S&P MidCap 400® Index with relatively high quality and value composite scores, which are computed pursuant to the index methodology. Under normal circumstances, the fund will invest at least 80% of the value of its net assets, plus the amount of any borrowings for investment purposes, in the components of the underlying index and in derivatives and other investments that have economic characteristics similar to the components of the underlying index.
GRPM top holdings
| Holding | Sector | Weight |
|---|---|---|
| Abercrombie & Fitch Company ANF | Consumer Cyclical | 3.37% |
| Halozyme Therapeutics Inc HALO | Healthcare | 2.96% |
| Duolingo Inc DUOL | Technology | 3.06% |
| InterDigital Inc IDCC | Technology | 2.69% |
| Hecla Mining Company HL | Basic Materials | 2.44% |
| Renaissancere Holdings Ltd RNR | Financial Services | 2.47% |
| Paylocity Holding Corporation PCTY | Technology | 2.36% |
| Appfolio Inc APPF | Technology | 2.40% |
| SharkNinja, Inc. SN | Consumer Cyclical | 2.42% |
| Qualys Inc QLYS | Technology | 2.40% |
Holdings with an ATLAS page link to their probability range, fair value and earnings calendar.
GRPM sector breakdown
| Sector | Weight |
|---|---|
| Financial Services | 23.2% |
| Technology | 22.6% |
| Healthcare | 20.3% |
| Consumer Cyclicals | 13.1% |
| Industrials | 10.5% |
| Energy | 4.8% |
| Basic Materials | 3.3% |
| Consumer Defensive | 2.3% |
By region: North America 97.1%, Latin America 1.8%, Europe Developed 1.1%.
GRPM returns and risk
| Year to date | +15.9% |
|---|---|
| 1 year | +21.7% |
| 3 years (annualised) | +19.0% |
| 5 years (annualised) | +10.1% |
| 10 years (annualised) | +11.5% |
| Volatility (3 years) | 18.0% |
| Sharpe ratio (3 years) | 0.70 |
Past returns do not guarantee future results.
GRPM: frequently asked questions
What does GRPM invest in?
Invesco S&P MidCap 400 GARP ETF invests in a portfolio of securities. Its largest holdings are Abercrombie & Fitch Company (3.4%), Halozyme Therapeutics Inc (3.0%), Duolingo Inc (3.1%), InterDigital Inc (2.7%), Hecla Mining Company (2.4%).
What is the GRPM expense ratio?
0.36% a year: about $36.00 for every $10,000 invested.
What is the GRPM dividend yield?
0.56%. ATLAS does not hold the exact distribution dates for ETFs.
Will GRPM go up?
Nobody can know. The ATLAS model puts the chance of a higher price in one month at 55%, with a likely range (50%) of $144.44 to $152.27 from $147.59 today. It is a probability, not a prediction.
How has GRPM performed?
Year to date +15.9%, one year +21.7%, three years +19.0% a year, five years +10.1% a year. Past returns do not guarantee future results.
Similar ETFs: Other strategies
- iShares Russell 1000 ETF (IWB)
- Vanguard Extended Market ETF (VXF)
- State Street SPDR S&P MidCap 400 ETF Trust (MDY)
- iShares S&P 100 ETF (OEF)
- iShares Russell 3000 ETF (IWV)
- Vanguard Mortgage-Backed Securities ETF (VMBS)
- State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF (SPTM)
- iShares Preferred and Income Securities ETF (PFF)
Educational information, not investment advice. Disclaimer